Editas Medicine

高管在Editas Medicine变化

James Mullen 曾任 Chairman of the Board, 现升职为 Chief Executive Officer and Chairman of the Board  (新闻发布的2021二月8号).
Cynthia Collins, Director and Chief Executive Officer, 已经离开公司  (新闻发布的2021二月8号).
Charles Albright, Executive Vice President and Chief Scientific Officer, 已经离开公司  (新闻发布的2021一月11号).

更多的变化在％s

创建提醒
跟踪 Editas Medicine 的高管变动

是其中之一......

• Russell 3000.

Editas Medicine 搜索最多的简介

• James Mullen, Chief Executive Officer and Chairman of the Board
• Andrew Hirsch, Director
• David Scadden, Director

单击任一高管查看其简介 >

Latest M&A news in 生物技术.

Amgen has announced the acquisition of Five Prime Therapeutics (posted on 3月 5, 2021).
Bio-Techne has announced the acquisition of Asuragen (posted on 3月 4, 2021).
Roivant Sciences has announced the acquisition of Silicon Therapeutics (posted on 2月 26, 2021).

生物技术 行业的其他推荐联系人

• Adaptimmune Therapeutics 企业 Tal Zaks - Non-Executive Director
• Gynesonics 企业 Chandra Leo - Director
• Axcella Health 企业 Stephen Hoge - Director

了解更多有关生物技术行业的信息 >

有关 Editas Medicine 的最新新闻

Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update | Editas Medicine
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update | Editas Medicine
Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer | Editas Medicine
Editas Medicine Announces Pricing of Offering of Common Stock | Editas Medicine
Editas Medicine Announces Offering of Common Stock | Editas Medicine

Editas Medicine 在 维基百科、谷歌新闻 和 雅虎财经

Editas Medicine 在 LinkedIn、叽叽喳喳 和 YouTube

Editas Medicine 拥有 1,568 家竞争者，其中包括 Biogen (美国(美洲))、Neptune Wellness Solutions (加拿大) 和 Eurofins (法国)。

通过电子邮件联系联系该企业高管，包括 Meeta Chatterjee

致电Editas Medicine，电话：+1 617...

查看组织结构图

Register to receive your alert

报告错误